ANAB vs LIN · rev $91.3M vs P/E 34, rev $33.99B
AnaptysBio Inc (ANAB) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
AnaptysBio Inc (ANAB) is a biotechnology company listed on NASDAQ.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported ANAB revenue for 2024-12-31 was $91.3M. Net income was -$145.2M. Revenue was up 432.0% from 2023-12-31 to 2024-12-31. ANAB currently screens at market cap $1.62B.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
ANAB currently screens at market cap $1.62B. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the ANAB and LIN stock pages for the full models.
Not investment advice.